LP-1Homo sapiens (Human)Cancer cell line
Also known as: LP1
Quick Overview
LP-1 is a human B-cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0012 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Peripheral blood[UBERON:UBERON_0000178] |
Donor Information
| Age | 56 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Multiple myeloma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Plasma Cell Myeloma |
| OncoTree Code | PCM |
DepMap Information
| Source Type | HSRRB |
|---|---|
| Source ID | ACH-000204_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Glu286Lys (c.856G>A) | Homozygous | - | PubMed=17332242, PubMed=16960149 |
| MutationSimple | TRAF3 | p.Lys286Ilefs*7 (c.857_870delAGAGCATACAAAGT) | Homozygous | - | PubMed=17692805 |
| MutationSimple | FGFR3 | p.Phe384Leu (c.1150T>C) (F386L) | Heterozygous | - | PubMed=27822414 |
| Gene fusion | IGH | IGH-NSD2, IGH-WHSC1 | - | - | PubMed=31160637 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Sirota M., Wiita A.P.
Leukemia 34:2754-2765(2020).
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
Pellat-Deceunynck C.
J. Hematol. Oncol. 11:137.1-137.13(2018).
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
Yang H.H., Koeffler H.P.
BMC Cancer 18:940.1-940.13(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
Cytometry A 87:285-288(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Pellat-Deceunynck C.
Haematologica 96:574-582(2011).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.
Fabris S., Lambertenghi-Deliliers G., Neri A.
BMC Med. Genomics 1:37.1-37.9(2008).
Characterization of MYC translocations in multiple myeloma cell lines.
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Stewart A.K., Carpten J.D., Bergsagel P.L.
Cancer Cell 12:131-144(2007).
Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Lambertenghi-Deliliers G., Bertoni F., Neri A.
Genes Chromosomes Cancer 46:226-238(2007).
The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.
Moreau P., Amiot M., Pellat-Deceunynck C.
Haematologica 91:1234-1240(2006).
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Kuehl W.M., Bergsagel P.L.
Blood 97:729-736(2001).
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Drexler H.G., Matsuo Y.
Leuk. Res. 24:681-703(2000).
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.";
Bataille F.-R., Amiot M.
Br. J. Haematol. 107:392-395(1999).
The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation.
Avanzi G.C.
Blood 73:1020-1027(1989).
The leukemia-lymphoma cell line factsbook.";
Drexler H.G.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
Multiple myeloma cell lines.";
Jernberg-Wiklund H., Nilsson K.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).